Alexion Pharmaceuticals, Inc. (ALXN)
$43.70
-0.46 (-1.04%)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $44.16 |
| Daily Range | $43.63 - $44.27 |
| 52-Week Range | $28.16 - $48.93 |
| Market Cap | $3.87B |
| P/E Ratio | 50.18 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 429,350 |
| Average Daily Volume | 777,000 |
ALXN
VS S&P 500 (SPY)
How do you think ALXN will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ALXN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ALXN News and Commentary
- The Hottest Sector for 2010 – The Motley Fool
- UPDATE 2-Alexion Q3 results beat Street, raises FY view – Reuters
- UPDATE 1-Alexion Q3 results beat Street, raises FY view – Reuters
- 2009-FEB-12 Bullish Industries - Oil&Gas Pipelines, Apparel Stores – Blog at The Motley Fool
- Earn 100% Per 3 Days – The Motley Fool
- Late to the Party – The Motley Fool
- Who's Next in the Biotech Buyout Frenzy? – Blog at The Motley Fool
- Small cap biotech investing in the era of underperformance – Blog at The Motley Fool
- A Top BioMarin Drug Heads Overseas – The Motley Fool
- The Start of a Biotech Buying Binge? – Blog at The Motley Fool
- 6 Stocks Splitting Shares – The Motley Fool
- Technical Analysis: A Damning Verdict – The Motley Fool
- BioMarin's New Drugs Mostly Hit Their Targets – The Motley Fool
- Get Ready for the Fall – The Motley Fool
- Start Making $53,200 Today – The Motley Fool
- 5 More Unloved Growth Stocks – The Motley Fool
- Soliris Brightens Alexion's Quarter – The Motley Fool
- Betting on Approval for This Orphan Drug – The Motley Fool
- PDL BioPharma's Split Decision – The Motley Fool
- FDA Approvals ... Increase? – The Motley Fool
RSS Headlines
Fool UK
